Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Stijn R. van Roessel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3041-0452; OpenAlex author ID A5040697057. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
129
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 3 papers · 2021: 7 papers · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 18

  1. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  2. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  3. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  4. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderl… Co-author DOI 10.1093/bjs/znad210↗
  5. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). First author DOI 10.1093/bjs/znac350↗
  6. Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11664-4↗
  7. Correction to: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic C… Co-author DOI 10.1245/s10434-022-12182-z↗
  8. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of t… Co-author DOI 10.1002/jso.26567↗
  9. Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis. Co-author DOI 10.1016/j.ejso.2020.11.145↗
  10. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Co-author DOI 10.1038/s41379-020-00683-9↗
  11. Scoring of tumour response after neoadjuvant therapy in resected pancreatic cancer: systematic review. Co-author DOI 10.1093/bjs/znaa031↗
  12. Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer: impact on short- and long-term outcomes in a nationwide cohort analysis. Co-author DOI 10.1093/bjs/znab345↗
  13. Resection of the Portal-Superior Mesenteric Vein in Pancreatic Cancer: Pathological Assessment and Recurrence Patterns. Co-author DOI 10.1097/mpa.0000000000001897↗
  14. Artificial Intelligence-Based Segmentation of Residual Tumor in Histopathology of Pancreatic Cancer after Neoadjuvant Treatment. Co-author DOI 10.3390/cancers13205089↗
  15. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  16. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.12.023↗
  17. Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. Co-author DOI 10.1245/s10434-020-08235-w↗
  18. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2018.3617↗

Closest collaborators

The 25 strongest of 129 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 16 shared papers, 2018–2025 · strength 1.62
  2. Bas Groot Koerkamp · 12 shared papers, 2018–2025 · strength 1.17
  3. Joanne Verheij · 9 shared papers, 2018–2022 · strength 0.92
  4. Bert A. Bonsing · 7 shared papers, 2020–2023 · strength 0.72
  5. Izaak Quintus Molenaar · 7 shared papers, 2020–2023 · strength 0.71
  6. Ignace H. J. T. de Hingh · 7 shared papers, 2020–2023 · strength 0.71
  7. Lodewijk A.A. Brosens · 6 shared papers, 2021–2022 · strength 0.63
  8. Vincent Erwin de Meijer · 6 shared papers, 2021–2023 · strength 0.62
  9. Martijn W.J. Stommel · 6 shared papers, 2020–2022 · strength 0.58
  10. Casper H.J. van Eijck · 6 shared papers, 2018–2023 · strength 0.56
  11. Sebastiaan Festen · 5 shared papers, 2021–2023 · strength 0.52
  12. Hjalmar C. van Santvoort · 5 shared papers, 2021–2022 · strength 0.49
  13. Johanna W. Wilmink · 5 shared papers, 2020–2023 · strength 0.49
  14. Boris V. Janssen · 4 shared papers, 2021–2022 · strength 0.44
  15. Geert Kazemier M · 4 shared papers, 2021–2022 · strength 0.41
  16. Lois A. Daamen · 4 shared papers, 2021–2022 · strength 0.40
  17. Vincent B. Nieuwenhuijs · 4 shared papers, 2021–2022 · strength 0.39
  18. Giuseppe Malleo · 4 shared papers, 2018–2025 · strength 0.36
  19. Claudio Luchini · 3 shared papers, 2021–2022 · strength 0.33
  20. Caroline Sophie Verbeke · 3 shared papers, 2021–2022 · strength 0.33
  21. Hanneke W.M. van Laarhoven · 3 shared papers, 2020–2025 · strength 0.31
  22. Jacob L. van Dam · 3 shared papers, 2018–2023 · strength 0.30
  23. Thijs J. Schouten · 3 shared papers, 2021–2022 · strength 0.30
  24. Tobias Keck · 3 shared papers, 2020–2025 · strength 0.30
  25. Asif Halimi · 3 shared papers, 2020–2025 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.